[Weekly HOT Stocks] Hanguk Pharma, No.1 in Individual Net Purchases on KOSDAQ

General Subscription Competition Rate 2036 to 1... Opening Price Set at Twice the Public Offering Price of 18,000 Won

[Asia Economy Reporter Geum Bo-ryeong] Korea Pharma, which was listed on the KOSDAQ market on the 10th, attracted great interest from individual investors for a week.

According to the Korea Exchange on the 16th, Korea Pharma ranked first among the top stocks in net purchases by individual investors on the KOSDAQ market from the 10th to the 14th. During this period, individual investors net purchased Korea Pharma stocks worth 34.6 billion KRW.

Founded in 1974, Korea Pharma is a comprehensive pharmaceutical company specializing in pharmaceutical research and development, manufacturing, and sales. It mainly focuses on the central nervous system, digestive system, and circulatory system.

According to Eugene Investment & Securities, as of last year, the sales proportion by business sector was 78.8% for ethical pharmaceuticals (ETC), 19.7% for contract manufacturing organizations (CMO), and 1.5% for others. Within the ETC sector, the breakdown was 43% central nervous system, 12% digestive system, 9% circulatory system, 7% antibiotics and antimicrobials, and 30% other prescription drugs. Among central nervous system ethical pharmaceuticals, the order was 29% antipsychotics, 29% dementia treatments, 22% antidepressants, 7% anticonvulsants, 6% anxiolytics, and 7% others.

Korea Pharma is also actively introducing original drugs. Mungyeong-jun, a researcher at IBK Investment & Securities, said, "Last year, Korea Pharma secured the domestic exclusive rights for PLENVU bowel cleansing agent from the Dutch pharmaceutical company Norgine." He explained, "PLENVU is the world's first 1L polyethylene glycol (PEG) bowel cleansing agent. It is a low-dose bowel cleansing agent that improves patient medication convenience, making it likely to easily enter the hospital and clinic market."

Korea Pharma initially expected the public offering price band to be 6,500 to 8,500 KRW but finalized the offering price at 9,000 KRW, exceeding expectations. The demand forecast competition rate for institutional investors was 1,296.86 to 1. The general subscription competition rate was also remarkably high at 2,035.74 to 1.

On the 10th, the opening price recorded 18,000 KRW, double the public offering price. The stock price fluctuated during the week and closed at 16,100 KRW on the 14th.

This content was produced with the assistance of AI translation services.